Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Seock-Ah Im

Professor

Seoul National University College of Medicine

South Korea

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Obstetrics And Gynecology

30%

Oncology

100%

Ovarian Cancer

70%

Targeted Therapy

70%

Neoadjuvant Therapy

70%

Hormone Therapy

50%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles24

Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)

Article Link

Year:

2025

Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer

Article Link

Year:

2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies

Article Link

Year:

2025

BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

Article Link

Year:

2025

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Article Link

Year:

2024

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Article Link

Year:

2024

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study

Article Link

Year:

2024

Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

Article Link

Year:

2024

Tracing the evolutionary history of breast cancer

Article Link

Year:

2024

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Article Link

Year:

2024

Differences in severity of chemotherapy-induced nausea and vomiting between neoadjuvant and adjuvant chemotherapy in patients with breast cancer: analysis of data from two prospective observational studies

Article Link

Year:

2024

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Article Link

Year:

2024

Reply to Y. Yoshitomi et al

Article Link

Year:

2024

Margetuximab Versus Trastuzumab in Patients with Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results from a Randomized Phase 3 Trial

Article Link

Year:

2023

Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor–Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial

Article Link

Year:

2023

Olaparib efficacy in patients with germline BRCA‐mutated, HER2‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial

Article Link

Year:

2023

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Article Link

Year:

2023

The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer

Article Link

Year:

2023

The Effect of Temperament on the Association Between Pre-treatment Anxiety and Chemotherapy-Related Symptoms in Patients With Breast Cancer

Article Link

Year:

2022

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Article Link

Year:

2022

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

Article Link

Year:

2022

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

Article Link

Year:

2022

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

Article Link

Year:

2022

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Article Link

Year:

2022

Collaborators16

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

Min-Sup Shin

Seoul National University

SOUTH KOREA

SONIA PERNAS SIMON

Associate Professor

University of Barcelona

SPAIN

Sherene Loi

University of Melbourne

AUSTRALIA

norikazu masuda

Professor

Nagoya University Graduate School of Medicine

JAPAN

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA

Julie Gralow

Chief Medical Officer

UNITED STATES

yvette drew

Associate Professor

The University of British Columbia

CANADA

Antonino Musolino

Associate Professor

University of Parma

ITALY

Koung Jin Suh

Seoul National University Hospital

SOUTH KOREA

Masakazu Toi

JAPAN

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

Véronique Dieras

Head Breast Group

FRANCE

Yongsik Jung

Associate Professor

Ajou University School of Medicine

SOUTH KOREA

Sung-Bae Kim

University of Ulsan College of Medicine

SOUTH KOREA

Se Hyun Kim

Seoul National University Hospital

SOUTH KOREA

How do I reach out?

Meet Kite AI